Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Methods: Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 23; no. 3; pp. 533 - 539
Main Authors Mendivil, Alberto A., Micha, John P., Brown, John V., Rettenmaier, Mark A., Abaid, Lisa N., Lopez, Katrina L., Goldstein, Bram H.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.03.2013
Copyright by IGCS and ESGO
Elsevier Limited
Subjects
Online AccessGet full text
ISSN1048-891X
1525-1438
1525-1438
DOI10.1097/IGC.0b013e31828566f1

Cover

Abstract We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Methods: Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m2) and vorinostat (400 mg) maintenance chemotherapy every 28 days. Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure. Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.
AbstractList We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days. Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study's closure. Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.
OBJECTIVESWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. METHODSPatients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board–approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days. RESULTSEighteen patients received a combined 90 cycles (median, 6 cycles; range, 1–6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1–12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure. CONCLUSIONSBecause the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.
ObjectivesWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.MethodsPatients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board–approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m2) and vorinostat (400 mg) maintenance chemotherapy every 28 days.ResultsEighteen patients received a combined 90 cycles (median, 6 cycles; range, 1–6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1–12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure.ConclusionsBecause the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.
We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Methods: Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m2) and vorinostat (400 mg) maintenance chemotherapy every 28 days. Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure. Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.
We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.OBJECTIVESWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days.METHODSPatients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days.Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study's closure.RESULTSEighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study's closure.Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.CONCLUSIONSBecause the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.
Author Abaid, Lisa N.
Micha, John P.
Brown, John V.
Lopez, Katrina L.
Goldstein, Bram H.
Rettenmaier, Mark A.
Mendivil, Alberto A.
AuthorAffiliation Gynecologic Oncology Associates, Newport Beach; and †The Women’s Cancer Research Foundation, Newport Beach, CA
AuthorAffiliation_xml – name: Gynecologic Oncology Associates, Newport Beach; and †The Women’s Cancer Research Foundation, Newport Beach, CA
Author_xml – sequence: 1
  givenname: Alberto A.
  surname: Mendivil
  fullname: Mendivil, Alberto A.
  organization: Gynecologic Oncology Associates, Newport Beach
– sequence: 2
  givenname: John P.
  surname: Micha
  fullname: Micha, John P.
  organization: Gynecologic Oncology Associates, Newport Beach
– sequence: 3
  givenname: John V.
  surname: Brown
  fullname: Brown, John V.
  organization: Gynecologic Oncology Associates, Newport Beach
– sequence: 4
  givenname: Mark A.
  surname: Rettenmaier
  fullname: Rettenmaier, Mark A.
  organization: Gynecologic Oncology Associates, Newport Beach
– sequence: 5
  givenname: Lisa N.
  surname: Abaid
  fullname: Abaid, Lisa N.
  organization: Gynecologic Oncology Associates, Newport Beach
– sequence: 6
  givenname: Katrina L.
  surname: Lopez
  fullname: Lopez, Katrina L.
  organization: The Women’s Cancer Research Foundation, Newport Beach, CA
– sequence: 7
  givenname: Bram H.
  surname: Goldstein
  fullname: Goldstein, Bram H.
  email: bram@gynoncology.com
  organization: Gynecologic Oncology Associates, Newport Beach
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23385285$$D View this record in MEDLINE/PubMed
BookMark eNqFkktvEzEUhUeoiD7gHyBkiQ2LTrHn4cywQKqiJlSK1Egtj93IY99pXBx7sD0J-ZX8JW6Z0kXEY2Uvznfu8T0-Tg6ss5AkLxk9Y7SevL2cT89oS1kOOauyquS8Y0-SI1ZmZcqKvDrAOy2qtKrZl8PkOIQ7Smmd0fpZcpjleVUic5T8uLTSgwigCN60AiuBuI5cwwY8kLkI0TttI4SorTDkYgM2BvJZxxWZaR9iutAWyFJIo6P4DuaUTIVvXW8EAqdEWEU-Oa-tC1FEMl3B2sUVeNHvSOc8OVcbgSNVeh3FLZCLHo3BaJx0tRFeC7RYer0WfkeW4HXEHQgz2s6EMa5HCbkZWsCx6OOfJ087YQK8eDhPko-zi5vph3RxNb-cni9SWVQlS3ndZkWbt6yus3LCiiLnPKtUxWsOAjjtFIdCqrLgHW05ACg5EYpxWgNXbVHnJ0k5-g62F7stRmn6MWfDaHNfUKNvZbNfEHJvRq737tuAW23WOkgwRlhwQ2hYzjI2yWlZovT1nvTODR5LCE1WYnt5yX6pXj2ohnYN6jHF74pR8G4USO9C8NA1EpuK2tnohTaPcfE__SlusQfvv_IvWDViW2ci-PDVDFvwzQq7i6v_oe9HFLC9jUYqSH3_K5X2IGOjnP63wU_6YvWS
CitedBy_id crossref_primary_10_2217_nnm_14_50
crossref_primary_10_1016_j_gore_2017_03_007
crossref_primary_10_3390_ijms23052496
crossref_primary_10_3389_fchem_2022_948217
crossref_primary_10_3389_fonc_2014_00111
crossref_primary_10_3389_fcell_2020_560117
crossref_primary_10_1158_0008_5472_CAN_19_3837
crossref_primary_10_1159_000510131
crossref_primary_10_1186_s40360_016_0075_8
crossref_primary_10_1016_j_jddst_2019_03_018
crossref_primary_10_3389_fonc_2024_1437953
crossref_primary_10_3390_cancers13081769
crossref_primary_10_1590_S1516_8913201500132
crossref_primary_10_1016_j_ygyno_2017_01_009
crossref_primary_10_1089_crsi_2017_0016
crossref_primary_10_3390_biom5043438
crossref_primary_10_3390_jcm13030897
crossref_primary_10_1016_j_critrevonc_2017_06_007
crossref_primary_10_1007_s00280_015_2813_9
crossref_primary_10_3390_ijms242015066
Cites_doi 10.1007/s10147-011-0249-8
10.1200/JCO.2007.12.0782
10.1016/j.canlet.2009.01.002
10.7326/0003-4819-79-4-604
10.1186/1471-2407-6-183
10.1016/S0090-8258(03)00472-4
10.1006/gyno.1995.1140
10.1006/gyno.1997.4916
10.1002/cncr.21969
10.1111/j.0022-202X.2005.23925.x
10.1016/j.ygyno.2006.09.011
10.1097/IGC.0b013e3182070f17
10.1182/blood-2006-06-025999
10.1210/en.2006-0896
10.1158/1078-0432.CCR-03-0787
10.1016/j.ygyno.2009.09.039
10.1016/j.ygyno.2007.10.022
10.1200/JCO.1989.7.11.1748
10.1111/j.1447-0756.2010.01223.x
10.1016/j.ygyno.2008.01.009
10.1111/j.1525-1438.2007.00886.x
10.1016/S0090-8258(03)00128-8
10.1016/j.ygyno.2004.05.050
10.1016/j.ygyno.2007.06.004
10.1016/j.hoc.2011.10.004
10.1016/j.ejso.2008.01.005
10.1186/1755-8794-2-67
10.1158/1078-0432.CCR-05-2404
10.1002/jcp.22574
10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U
10.1093/jnci/92.3.205
10.1111/IGC.0b013e3181e94331
10.1200/JCO.2009.27.4696
10.1016/j.clbc.2011.04.002
ContentType Journal Article
Copyright 2013 IGCS and ESGO
Copyright © 2013 by IGCS and ESGO
Copyright © 2013 by IGCS and ESGO2013
Copyright_xml – notice: 2013 IGCS and ESGO
– notice: Copyright © 2013 by IGCS and ESGO
– notice: Copyright © 2013 by IGCS and ESGO2013
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
PQEST
PQQKQ
PQUKI
PRINS
7X8
ADTOC
UNPAY
DOI 10.1097/IGC.0b013e31828566f1
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

ProQuest One Academic Eastern Edition

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1525-1438
EndPage 539
ExternalDocumentID 10.1097/igc.0b013e31828566f1
23385285
10_1097_IGC_0b013e31828566f1
10.1097/IGC.0b013e31828566f1
S1048891X24019042
Genre Research Support, Non-U.S. Gov't
Clinical Trial, Phase II
Journal Article
GroupedDBID ---
.3N
.Z2
0R~
1OC
29J
31~
36B
4.4
53G
5GY
5VS
7X7
8-1
8FI
8FJ
AAHLL
AAKAS
AARTV
AAXUO
ABBUW
ABJNI
ABUWG
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACWDW
ACWRI
ACXNZ
ACXQS
ADZCM
AENEX
AFBPY
AFEBI
AFKRA
AFTRI
AFZJQ
AGINI
AHEFC
AIZYK
AJAOE
AJNYG
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AWKKM
BENPR
BFHJK
BQLVK
CAG
CCPQU
CO8
COF
CS3
CXRWF
DC6
DCZOG
E.X
EBS
EJD
EX3
F5P
FDB
FL-
FYUFA
FZ0
HAJ
HMCUK
HZI
HZ~
IHE
IN~
KD2
L-C
LH4
LW6
O9-
OCUKA
OHYEH
ORVUJ
OUVQU
OVD
OXXIT
P2P
RMJ
ROL
S4S
TEORI
UDS
UKHRP
V2I
W3M
W99
WOW
X3V
X3W
YUY
AAYWO
M41
AALRI
AAYXX
ACVFH
ADCNI
AEUPX
AFPUW
AIGII
AKBMS
AKYEP
CITATION
PHGZM
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
K9.
PQEST
PQQKQ
PQUKI
PRINS
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c4851-69b24b3b19925714436628d8696eae60fd6e4cd546f0b6eeedc7ad1609e6db493
IEDL.DBID 7X7
ISSN 1048-891X
1525-1438
IngestDate Tue Aug 26 13:29:38 EDT 2025
Sat Sep 27 18:55:34 EDT 2025
Mon Jun 30 13:23:13 EDT 2025
Mon Jul 21 06:04:10 EDT 2025
Wed Oct 01 05:49:25 EDT 2025
Thu Apr 24 22:56:31 EDT 2025
Fri May 16 03:51:30 EDT 2025
Sat Dec 28 15:51:36 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Carboplatin
Gynecologic oncology
Chemotherapy
Vorinostat
Paclitaxel
Ovarian cancer
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4851-69b24b3b19925714436628d8696eae60fd6e4cd546f0b6eeedc7ad1609e6db493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://ijgc.bmj.com/content/ijgc/23/3/533.full.pdf
PMID 23385285
PQID 2552835155
PQPubID 5161120
PageCount 7
ParticipantIDs unpaywall_primary_10_1097_igc_0b013e31828566f1
proquest_miscellaneous_1312173055
proquest_journals_2552835155
pubmed_primary_23385285
crossref_citationtrail_10_1097_IGC_0b013e31828566f1
crossref_primary_10_1097_IGC_0b013e31828566f1
wolterskluwer_health_10_1097_IGC_0b013e31828566f1
elsevier_sciencedirect_doi_10_1097_IGC_0b013e31828566f1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2013
2013-March
2013-03-00
2013-Mar
20130301
PublicationDateYYYYMMDD 2013-03-01
PublicationDate_xml – month: 03
  year: 2013
  text: March 2013
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Kidlington
PublicationTitle International journal of gynecological cancer
PublicationTitleAlternate Int J Gynecol Cancer
PublicationYear 2013
Publisher Elsevier Inc
Copyright by IGCS and ESGO
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Copyright by IGCS and ESGO
– name: Elsevier Limited
References Chobanian, Greenberg, Gass (bb0020) 2004; 24
Rustin, Marples, Nelstrop (bb0090) 2004; 10
Rose, Piver (bb0140) 1995; 57
Duvic, Talpur, Ni (bb0040) 2007; 109
Yardley, Raefsky, Castillo (bb0155) 2011; 11
Schorge, Eisenhauer, Chi (bb0130) 2012; 26
Eisenhauer, Abu-Rustum, Sonoda (bb0055) 2008; 108
(bb0080) 2010
Calvert, Newell, Gunbrell (bb0070) 1989; 7
Colombo, Mourregot, Fabbro (bb0125) 2009; 35
Zhang, Richon, Ni (bb0035) 2005; 125
Cannistra, Matulonis, Penson (bb0185) 2007; 25
Modesitt (bb0045) 2008; 109
Wright, Hagemann, Rader (bb0190) 2006; 107
Micha, Goldstein, Rettenmaier (bb0015) 2004; 94
Kim, Kim, Wu (bb0145) 2010; 36
Sonnemann, Gänge, Pilz (bb0030) 2006; 6
Erjala, Sundvall, Junttila (bb0175) 2006; 12
de Haan, van den Berg (bb0150) 2006; 29
Simpkins, Belinson, Rose (bb0195) 2007; 107
Siegel, Naishadham, Jemal (bb0005) 2012; 62
Romanini, Tanganelli, Carnino (bb0115) 2003; 89
Uchida, Maruyama, Ono (bb0180) 2007; 148
Muraoka, Tsukuda, Toyooka (bb0165) 2011; 16
Micha, Goldstein, Rettenmaier (bb0120) 2007; 17
Richon, Garcia-Vargas, Hardwick (bb0105) 2009; 280
Brown, Micha, Rettenmaier (bb0135) 2010; 20
Stuart (bb0110) 2003; 90
du Bois, Herrstedt, Hardy-Bessard (bb0010) 2010; 28
Therasse, Arbuck (bb0085) 2000; 92
.
Brown, Rettenmaier, Dillman (bb0060) 1998; 68
Rustin, Vergote, Eisenhauer (bb0095) 2011; 21
Jelliffe (bb0075) 1973; 79
Dietrich, Greenberg, DeSimone (bb0025) 2010; 116
Cooper, Greenberg, Lancaster (bb0050) 2007; 104
Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents.
2007;4:337-343.
Hainsworth, Greco (bb0065) 1994; 74
LaBonte, Wilson, Fazzone (bb0160) 2009; 2
Bruzzese, Leone, Rocco (bb0170) 2011; 226
Calvert (10.1097/IGC.0b013e31828566f1_bb0070) 1989; 7
Bruzzese (10.1097/IGC.0b013e31828566f1_bb0170) 2011; 226
Micha (10.1097/IGC.0b013e31828566f1_bb0120) 2007; 17
Simpkins (10.1097/IGC.0b013e31828566f1_bb0195) 2007; 107
Cooper (10.1097/IGC.0b013e31828566f1_bb0050) 2007; 104
Richon (10.1097/IGC.0b013e31828566f1_bb0105) 2009; 280
Erjala (10.1097/IGC.0b013e31828566f1_bb0175) 2006; 12
Colombo (10.1097/IGC.0b013e31828566f1_bb0125) 2009; 35
Micha (10.1097/IGC.0b013e31828566f1_bb0015) 2004; 94
Cannistra (10.1097/IGC.0b013e31828566f1_bb0185) 2007; 25
Brown (10.1097/IGC.0b013e31828566f1_bb0135) 2010; 20
Dietrich (10.1097/IGC.0b013e31828566f1_bb0025) 2010; 116
Eisenhauer (10.1097/IGC.0b013e31828566f1_bb0055) 2008; 108
du Bois (10.1097/IGC.0b013e31828566f1_bb0010) 2010; 28
10.1097/IGC.0b013e31828566f1_or0005
Stuart (10.1097/IGC.0b013e31828566f1_bb0110) 2003; 90
Chobanian (10.1097/IGC.0b013e31828566f1_bb0020) 2004; 24
Kim (10.1097/IGC.0b013e31828566f1_bb0145) 2010; 36
Zhang (10.1097/IGC.0b013e31828566f1_bb0035) 2005; 125
Romanini (10.1097/IGC.0b013e31828566f1_bb0115) 2003; 89
Rustin (10.1097/IGC.0b013e31828566f1_bb0095) 2011; 21
Jelliffe (10.1097/IGC.0b013e31828566f1_bb0075) 1973; 79
Rustin (10.1097/IGC.0b013e31828566f1_bb0090) 2004; 10
Siegel (10.1097/IGC.0b013e31828566f1_bb0005) 2012; 62
(10.1097/IGC.0b013e31828566f1_bb0080) 2010
Duvic (10.1097/IGC.0b013e31828566f1_bb0040) 2007; 109
Therasse (10.1097/IGC.0b013e31828566f1_bb0085) 2000; 92
Uchida (10.1097/IGC.0b013e31828566f1_bb0180) 2007; 148
Schorge (10.1097/IGC.0b013e31828566f1_bb0130) 2012; 26
LaBonte (10.1097/IGC.0b013e31828566f1_bb0160) 2009; 2
Muraoka (10.1097/IGC.0b013e31828566f1_bb0165) 2011; 16
Rose (10.1097/IGC.0b013e31828566f1_bb0140) 1995; 57
Hainsworth (10.1097/IGC.0b013e31828566f1_bb0065) 1994; 74
de Haan (10.1097/IGC.0b013e31828566f1_bb0150) 2006; 29
Yardley (10.1097/IGC.0b013e31828566f1_bb0155) 2011; 11
10.1097/IGC.0b013e31828566f1_or0010
Wright (10.1097/IGC.0b013e31828566f1_bb0190) 2006; 107
Modesitt (10.1097/IGC.0b013e31828566f1_bb0045) 2008; 109
Sonnemann (10.1097/IGC.0b013e31828566f1_bb0030) 2006; 6
Brown (10.1097/IGC.0b013e31828566f1_bb0060) 1998; 68
References_xml – volume: 25
  start-page: 5180
  year: 2007
  end-page: 5186
  ident: bb0185
  article-title: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
  publication-title: J Clin Oncol.
– volume: 24
  start-page: 539
  year: 2004
  end-page: 545
  ident: bb0020
  article-title: Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status
  publication-title: .
– volume: 226
  start-page: 2378
  year: 2011
  end-page: 2390
  ident: bb0170
  article-title: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
  publication-title: .
– volume: 109
  start-page: 182
  year: 2008
  end-page: 186
  ident: bb0045
  article-title: Sill M, Hoffman JS, et al; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
  publication-title: .
– volume: 57
  start-page: 270
  year: 1995
  end-page: 272
  ident: bb0140
  article-title: Intestinal perforation secondary to paclitaxel
  publication-title: .
– volume: 109
  start-page: 31
  year: 2007
  end-page: 39
  ident: bb0040
  article-title: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
  publication-title: .
– volume: 6
  start-page: 183
  year: 2006
  ident: bb0030
  article-title: Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
  publication-title: .
– volume: 7
  start-page: 1748
  year: 1989
  end-page: 1756
  ident: bb0070
  article-title: Carboplatin dosage: prospective evaluation of a simple formula based on renal function
  publication-title: .
– volume: 79
  start-page: 605
  year: 1973
  ident: bb0075
  article-title: Creatinine clearance: bedside estimate
  publication-title: .
– volume: 20
  start-page: 1132
  year: 2010
  end-page: 1136
  ident: bb0135
  article-title: A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma
  publication-title: .
– volume: 62
  start-page: 10
  year: 2012
  end-page: 29
  ident: bb0005
  article-title: Cancer statistics, 2012
  publication-title: .
– volume: 280
  start-page: 201
  year: 2009
  end-page: 210
  ident: bb0105
  article-title: Development of vorinostat: current applications and future perspectives for cancer therapy
  publication-title: .
– volume: 108
  start-page: 276
  year: 2008
  end-page: 281
  ident: bb0055
  article-title: The effect of maximal surgical cytoreduction on sensitivity to platinum- taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer
  publication-title: .
– volume: 26
  start-page: 93
  year: 2012
  end-page: 109
  ident: bb0130
  article-title: Current surgical management of ovarian cancer
  publication-title: .
– volume: 148
  start-page: 896
  year: 2007
  end-page: 902
  ident: bb0180
  article-title: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin
  publication-title: Endocrinology.
– volume: 36
  start-page: 598
  year: 2010
  end-page: 604
  ident: bb0145
  article-title: Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience
  publication-title: .
– volume: 94
  start-page: 719
  year: 2004
  end-page: 724
  ident: bb0015
  article-title: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer
  publication-title: .
– volume: 74
  start-page: 1
  year: 1994
  ident: bb0065
  article-title: Paclitaxel administered by 1-hour infusion
  publication-title: .
– volume: 12
  start-page: 4103
  year: 2006
  end-page: 4111
  ident: bb0175
  article-title: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells
  publication-title: Clin Cancer Res.
– year: 2010
  ident: bb0080
  publication-title: National Cancer Institute: Common Terminology Criteria for Adverse Events (version 4.03)
– volume: 90
  start-page: S8
  year: 2003
  end-page: S15
  ident: bb0110
  article-title: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer
  publication-title: .
– volume: 92
  start-page: 205
  year: 2000
  end-page: 216
  ident: bb0085
  article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada
  publication-title: .
– volume: 11
  start-page: 297
  year: 2011
  end-page: 305
  ident: bb0155
  article-title: Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer
  publication-title: .
– volume: 107
  start-page: 118
  year: 2007
  end-page: 123
  ident: bb0195
  article-title: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
  publication-title: .
– reference: Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents.
– volume: 68
  start-page: 166
  year: 1998
  end-page: 168
  ident: bb0060
  article-title: Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer
  publication-title: .
– volume: 21
  start-page: 419
  year: 2011
  end-page: 423
  ident: bb0095
  article-title: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
  publication-title: .
– volume: 2
  start-page: 67
  year: 2009
  ident: bb0160
  article-title: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
  publication-title: .
– volume: 35
  start-page: 135
  year: 2009
  end-page: 143
  ident: bb0125
  article-title: Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients
  publication-title: .
– volume: 10
  start-page: 3919
  year: 2004
  end-page: 3926
  ident: bb0090
  article-title: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
  publication-title: .
– reference: .
– reference: 2007;4:337-343.
– volume: 17
  start-page: 771
  year: 2007
  end-page: 776
  ident: bb0120
  article-title: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
  publication-title: .
– volume: 29
  start-page: 541
  year: 2006
  end-page: 542
  ident: bb0150
  article-title: Colonic perforation secondary to taxol therapy: an unusual presentation
  publication-title: .
– volume: 125
  start-page: 1045
  year: 2005
  end-page: 1052
  ident: bb0035
  article-title: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action
  publication-title: .
– volume: 16
  start-page: 774
  year: 2011
  end-page: 777
  ident: bb0165
  article-title: Ileal perforation induced by acute radiation injury under gefitinib treatment
  publication-title: Int J Clin Oncol.
– volume: 28
  start-page: 4162
  year: 2010
  end-page: 4169
  ident: bb0010
  article-title: Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
  publication-title: .
– volume: 104
  start-page: 596
  year: 2007
  end-page: 601
  ident: bb0050
  article-title: In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer
  publication-title: .
– volume: 107
  start-page: 83
  year: 2006
  end-page: 89
  ident: bb0190
  article-title: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis
  publication-title: .
– volume: 116
  start-page: 126
  year: 2010
  end-page: 130
  ident: bb0025
  article-title: Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines
  publication-title: .
– volume: 89
  start-page: 354
  year: 2003
  end-page: 359
  ident: bb0115
  article-title: First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients
  publication-title: .
– volume: 16
  start-page: 774
  year: 2011
  ident: 10.1097/IGC.0b013e31828566f1_bb0165
  article-title: Ileal perforation induced by acute radiation injury under gefitinib treatment
  publication-title: Int J Clin Oncol.
  doi: 10.1007/s10147-011-0249-8
– volume: 25
  start-page: 5180
  year: 2007
  ident: 10.1097/IGC.0b013e31828566f1_bb0185
  article-title: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2007.12.0782
– volume: 280
  start-page: 201
  year: 2009
  ident: 10.1097/IGC.0b013e31828566f1_bb0105
  article-title: Development of vorinostat: current applications and future perspectives for cancer therapy
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2009.01.002
– volume: 79
  start-page: 605
  year: 1973
  ident: 10.1097/IGC.0b013e31828566f1_bb0075
  article-title: Creatinine clearance: bedside estimate
  publication-title: Ann Intern Med.
  doi: 10.7326/0003-4819-79-4-604
– volume: 29
  start-page: 541
  year: 2006
  ident: 10.1097/IGC.0b013e31828566f1_bb0150
  article-title: Colonic perforation secondary to taxol therapy: an unusual presentation
  publication-title: Onkologie.
– volume: 6
  start-page: 183
  year: 2006
  ident: 10.1097/IGC.0b013e31828566f1_bb0030
  article-title: Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
  publication-title: BMC Cancer.
  doi: 10.1186/1471-2407-6-183
– ident: 10.1097/IGC.0b013e31828566f1_or0005
– volume: 90
  start-page: S8
  year: 2003
  ident: 10.1097/IGC.0b013e31828566f1_bb0110
  article-title: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer
  publication-title: Gynecol Oncol.
  doi: 10.1016/S0090-8258(03)00472-4
– volume: 57
  start-page: 270
  year: 1995
  ident: 10.1097/IGC.0b013e31828566f1_bb0140
  article-title: Intestinal perforation secondary to paclitaxel
  publication-title: Gynecol Oncol.
  doi: 10.1006/gyno.1995.1140
– volume: 68
  start-page: 166
  year: 1998
  ident: 10.1097/IGC.0b013e31828566f1_bb0060
  article-title: Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer
  publication-title: Gynecol Oncol.
  doi: 10.1006/gyno.1997.4916
– volume: 24
  start-page: 539
  year: 2004
  ident: 10.1097/IGC.0b013e31828566f1_bb0020
  article-title: Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status
  publication-title: Anticancer Res.
– volume: 107
  start-page: 83
  year: 2006
  ident: 10.1097/IGC.0b013e31828566f1_bb0190
  article-title: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis
  publication-title: Cancer.
  doi: 10.1002/cncr.21969
– volume: 125
  start-page: 1045
  year: 2005
  ident: 10.1097/IGC.0b013e31828566f1_bb0035
  article-title: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action
  publication-title: J Invest Dermatol.
  doi: 10.1111/j.0022-202X.2005.23925.x
– volume: 104
  start-page: 596
  year: 2007
  ident: 10.1097/IGC.0b013e31828566f1_bb0050
  article-title: In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer
  publication-title: Gynecol Oncol.
  doi: 10.1016/j.ygyno.2006.09.011
– year: 2010
  ident: 10.1097/IGC.0b013e31828566f1_bb0080
– volume: 21
  start-page: 419
  year: 2011
  ident: 10.1097/IGC.0b013e31828566f1_bb0095
  article-title: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
  publication-title: Int J Gynecol Cancer.
  doi: 10.1097/IGC.0b013e3182070f17
– volume: 62
  start-page: 10
  year: 2012
  ident: 10.1097/IGC.0b013e31828566f1_bb0005
  article-title: Cancer statistics, 2012
  publication-title: CA Cancer J Clin.
– volume: 109
  start-page: 31
  year: 2007
  ident: 10.1097/IGC.0b013e31828566f1_bb0040
  article-title: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
  publication-title: Blood.
  doi: 10.1182/blood-2006-06-025999
– volume: 148
  start-page: 896
  year: 2007
  ident: 10.1097/IGC.0b013e31828566f1_bb0180
  article-title: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin
  publication-title: Endocrinology.
  doi: 10.1210/en.2006-0896
– volume: 10
  start-page: 3919
  year: 2004
  ident: 10.1097/IGC.0b013e31828566f1_bb0090
  article-title: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-03-0787
– volume: 116
  start-page: 126
  year: 2010
  ident: 10.1097/IGC.0b013e31828566f1_bb0025
  article-title: Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines
  publication-title: Gynecol Oncol.
  doi: 10.1016/j.ygyno.2009.09.039
– volume: 108
  start-page: 276
  year: 2008
  ident: 10.1097/IGC.0b013e31828566f1_bb0055
  article-title: The effect of maximal surgical cytoreduction on sensitivity to platinum- taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer
  publication-title: Gynecol Oncol.
  doi: 10.1016/j.ygyno.2007.10.022
– volume: 7
  start-page: 1748
  year: 1989
  ident: 10.1097/IGC.0b013e31828566f1_bb0070
  article-title: Carboplatin dosage: prospective evaluation of a simple formula based on renal function
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.1989.7.11.1748
– volume: 36
  start-page: 598
  year: 2010
  ident: 10.1097/IGC.0b013e31828566f1_bb0145
  article-title: Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience
  publication-title: J Obstet Gynaecol Res.
  doi: 10.1111/j.1447-0756.2010.01223.x
– volume: 109
  start-page: 182
  year: 2008
  ident: 10.1097/IGC.0b013e31828566f1_bb0045
  article-title: Sill M, Hoffman JS, et al; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
  publication-title: Gynecol Oncol.
  doi: 10.1016/j.ygyno.2008.01.009
– ident: 10.1097/IGC.0b013e31828566f1_or0010
– volume: 17
  start-page: 771
  year: 2007
  ident: 10.1097/IGC.0b013e31828566f1_bb0120
  article-title: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
  publication-title: Int J Gynecol Cancer.
  doi: 10.1111/j.1525-1438.2007.00886.x
– volume: 89
  start-page: 354
  year: 2003
  ident: 10.1097/IGC.0b013e31828566f1_bb0115
  article-title: First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients
  publication-title: Gynecol Oncol.
  doi: 10.1016/S0090-8258(03)00128-8
– volume: 94
  start-page: 719
  year: 2004
  ident: 10.1097/IGC.0b013e31828566f1_bb0015
  article-title: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer
  publication-title: Gynecol Oncol.
  doi: 10.1016/j.ygyno.2004.05.050
– volume: 107
  start-page: 118
  year: 2007
  ident: 10.1097/IGC.0b013e31828566f1_bb0195
  article-title: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
  publication-title: Gynecol Oncol.
  doi: 10.1016/j.ygyno.2007.06.004
– volume: 26
  start-page: 93
  year: 2012
  ident: 10.1097/IGC.0b013e31828566f1_bb0130
  article-title: Current surgical management of ovarian cancer
  publication-title: Hematol Oncol Clin North Am.
  doi: 10.1016/j.hoc.2011.10.004
– volume: 35
  start-page: 135
  year: 2009
  ident: 10.1097/IGC.0b013e31828566f1_bb0125
  article-title: Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients
  publication-title: Eur J Surg Oncol.
  doi: 10.1016/j.ejso.2008.01.005
– volume: 2
  start-page: 67
  year: 2009
  ident: 10.1097/IGC.0b013e31828566f1_bb0160
  article-title: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
  publication-title: BMC Med Genomics.
  doi: 10.1186/1755-8794-2-67
– volume: 12
  start-page: 4103
  year: 2006
  ident: 10.1097/IGC.0b013e31828566f1_bb0175
  article-title: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-2404
– volume: 226
  start-page: 2378
  year: 2011
  ident: 10.1097/IGC.0b013e31828566f1_bb0170
  article-title: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
  publication-title: J Cell Physiol.
  doi: 10.1002/jcp.22574
– volume: 74
  start-page: 1
  year: 1994
  ident: 10.1097/IGC.0b013e31828566f1_bb0065
  article-title: Paclitaxel administered by 1-hour infusion
  publication-title: Cancer.
  doi: 10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U
– volume: 92
  start-page: 205
  year: 2000
  ident: 10.1097/IGC.0b013e31828566f1_bb0085
  article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada
  publication-title: J Natl Cancer Inst.
  doi: 10.1093/jnci/92.3.205
– volume: 20
  start-page: 1132
  year: 2010
  ident: 10.1097/IGC.0b013e31828566f1_bb0135
  article-title: A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma
  publication-title: Int J Gynecol Cancer.
  doi: 10.1111/IGC.0b013e3181e94331
– volume: 28
  start-page: 4162
  year: 2010
  ident: 10.1097/IGC.0b013e31828566f1_bb0010
  article-title: Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2009.27.4696
– volume: 11
  start-page: 297
  year: 2011
  ident: 10.1097/IGC.0b013e31828566f1_bb0155
  article-title: Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer
  publication-title: Clin Breast Cancer.
  doi: 10.1016/j.clbc.2011.04.002
SSID ssj0009209
Score 2.1306243
Snippet We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage...
OBJECTIVESWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of...
We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage...
ObjectivesWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of...
SourceID unpaywall
proquest
pubmed
crossref
wolterskluwer
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 533
SubjectTerms Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Carboplatin
Carboplatin - administration & dosage
Chemotherapy
Cystadenocarcinoma, Serous - drug therapy
Cystadenocarcinoma, Serous - mortality
Cystadenocarcinoma, Serous - pathology
Endometrial Neoplasms - drug therapy
Endometrial Neoplasms - mortality
Endometrial Neoplasms - pathology
Fallopian Tube Neoplasms - drug therapy
Fallopian Tube Neoplasms - mortality
Fallopian Tube Neoplasms - pathology
Female
Follow-Up Studies
Gastrointestinal Diseases - chemically induced
Gastrointestinal Diseases - epidemiology
Genital cancers
Gynecologic oncology
Gynecological cancer
Humans
Hydroxamic Acids - administration & dosage
Incidence
Middle Aged
Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Staging
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - mortality
Ovarian Neoplasms - pathology
Ovaries
Paclitaxel
Paclitaxel - administration & dosage
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - mortality
Peritoneal Neoplasms - pathology
Prognosis
Prospective Studies
Response rates
Survival Rate
Vorinostat
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELagk0AT4nWMooGMxMc5TeLUST5WVbuBtFGJFsqnyHbc0S1LojZljD_JX-KuTirYgGnforycc9Kd_Zzv7jEhb1XMPeHriKWxiVkQuJpFXCvma60jHslYBdg7fHQsDifB-2l3Wvdxr3thTk-0o85PbTsDEjTl1fpmx-cd3gFw4uC-tFOms7tkS2BWqUW2Jsej3hfLOxCxKPama5ZUv8vwcO-mYS4OO3MQvtn58yOAMjPvXwvSdcC5Te6v8lJeXsgs2yYPLgrMZy_P1uXsvy1Kw0dk3Khja1HOnFWlHP3jCtPjLfV9TB7WIJX2rFU9IXdM_pTcO6rT8M_IT5hVsJjdpBSu7LGktJjRjwYcw9ADuawWBRJRwPyBggZYVLmkn-fVVzqcA95kEAIbOpIaKcK_m2yf9uVCFSUW5uX7VOYp_YSVgQX2O1EkNagbxS4pgGzaqwsXGEDlE0MHJTaWZOBJ9MM3iP0liBhZFg06Ag9DvnGZWbFDLDQo4RU6XikDw4KcxQ6ZDAfj_iGrT4ZgOgCIyESs_EBxhbWz3RBiQi6EH6WRiIWRRrizVJhAp91AzFwlDOAAHcrUE25sRKqCmD8nrRzGfkGoJwCDpQiDPAkPAhW6vlYul26oedSVbcIb80h0TZuOp3dkSZO-f3fQT64aVZuwzVelVfiG98PG8pIa-lhIk8DKdsOXe42hJvX0s0wgTkQePcCKbfJm8xgmDswGydwUq2XicQ_CUSR8a5Nda-CbX_U5qA4DtImzsfhreoAz_eVvvD_cIrHdvP_V4OVtB9kjrWqxMq8ADVbqde39vwCmvlve
  priority: 102
  providerName: Unpaywall
Title Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
URI https://dx.doi.org/10.1097/IGC.0b013e31828566f1
https://www.ncbi.nlm.nih.gov/pubmed/23385285
https://www.proquest.com/docview/2552835155
https://www.proquest.com/docview/1312173055
https://ijgc.bmj.com/content/ijgc/23/3/533.full.pdf
UnpaywallVersion publishedVersion
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1525-1438
  dateEnd: 20141231
  omitProxy: true
  ssIdentifier: ssj0009209
  issn: 1525-1438
  databaseCode: 7X7
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central Database Suite (ProQuest)
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1525-1438
  dateEnd: 20141231
  omitProxy: true
  ssIdentifier: ssj0009209
  issn: 1525-1438
  databaseCode: BENPR
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZgk4AJIX6OwJiMxOPMkjh1kidUqnYDaSWCFbqnyHbcUS1KQtMy9lfyL3HXOC0w2J4SKYmdk8_2d77v7gh5pWLuCV9HLItNzILA1SziWjFfax3xSMYqwNjho6E4HAXvx52xPXCrLa2yXROXC3VWajwj3wfoi6nBYPt7U31jWDUKvau2hMZNsukBVEGtDsfhOuluQ_EAiyNiUeyN29C5ONx_d9BbnwH6EYCaife_reky9NwitxdFJS_OZZ5vkbvnJXq267Mlsf237Wlwn9yzuJJ2G0V4QG6Y4iG5dWQ954_IT1gIkH9uMgp3TSVRWk7oJwO6bOiBrOezEnNHwJTHhvrIg6zpl-n8Kx1MASIysFoNTaTGrN4_TL5He3Kmygq5dMUelUVGPyOZr8QQJYp5CGxs1wUFXEy7lmvAAN2eGtqvMBYkB-WnH76DuS6hiaRJfEETmBSYIlzmTbMD5AZU8Ao9XigD3UI7s8dkNOgf9w6ZLebAdACojolY-YHiCumunRDMOC6EH2WRiIWRRriTTJhAZ51ATFwlDGzdOpSZJ9zYiEwFMX9CNgro-ymhngDYlCFy8SQ8CFTo-lq5XLqh5lFHOoS345hqm-kcC27kaetxh9FP_x59h7DVV1Uj8DXvh62KpBatNCgkhc3omi93Wo1K7YpRp2v9dsjL1WOY6-jAkYUpF3XqcQ8sSMzR5pDtRhNXv-pzEB06cMjrlWpekmN6qv_xN94f-ps2AbhXSvDsagmekzv-smoIUvV2yMZ8tjAvALvN1e5ygu6Szbf9YfIRrqNh0j35BbnvQhI
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLWmITEmhPgmMMBI8DazfLhO8oDQVNq1bB2V6KBvwXbcUREloWkp_VP8Ff4S9zZJCwy2p71FSmLH8r3Xx_G55xLyXIWeI1wdsDg0IePc1izwtGKu1jrwAhkqjrnDvWPROeFvh43hBvlR58IgrbKOictAHWca_5HvAfRFaTBY_l7nXxlWjcLT1bqERmkWh2Yxhy1b8ar7Bub3heu2W4Nmh1VVBZjmAC-YCJXLlaeQd9nwYT_hCeEGcSBCYaQR9igWhuu4wcXIVsLAGqJ9GTvCDo2IFUfxJQj5V7hnc9Tq94f-WuS3pJTADidgQegM61S90N_rHjTX_xzdAEDUyPnfUngW6m6TrVmay8VcJsk2uT7P8CS9-LIk0v-2HLZvkhsVjqX7peHdIhsmvU2u9qqT-jvkJwQe5LubmMJVWbmUZiP63oDvGHogi-kkQ60KCDHYUAt5lwX9OJ5-pu0xQFIGu2RD-1Kjivh3k-zSppyoLEfuXrpLZRrTD0gezDAliqLuQZVLtqCAw-l-xW1ggKZPDW3lmHuSgLPRd98kOB000S-FNmgfnBAlyWVSNttGLkIOj9DBTBnoFtqZ3CUnlzLN98hmCn0_INQRANNiREqOhBtc-barle1J29de0JAW8ep5jHSlrI4FPpKoPuGH2Y_-nn2LsNVbeTngC573axOJKnRUop4IFr8L3typLSqqIlQRrf3JIs9WtyG24IGRTE02KyLHc2DHippwFrlfWuLqU10Phg4dWOTlyjTPjGN8qv_xNc4f9huVCb_njuDh-SN4SrY6g95RdNQ9PnxErrnLiiVIE9whm9PJzDwG3DhVT5bOSsmny44OvwCkVHsk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLamIQ0mhPinMMBIcDfTJHad5AKhqWu3MjYqsUHvgu24oyJKQtNS-mq8BK_EOU3SAoPtaneRktixzt_n-DvnEPJch9yVnglYHNqQCeEYFnCjmWeMCXigQi0wd_jwSO6fiDeD1mCN_KhzYZBWWfvEhaOOM4P_yJsAfbE0GIS_5rCiRfR3u6_zrww7SOFJa91Oo1SRAzufwfateNXbBVm_8Lxu57i9z6oOA8wIgBpMhtoTmmvkYLZ82FtwKb0gDmQorbLSGcbSChO3hBw6WlqIJ8ZXsSud0MpYCyzEBO7_is8FRzqZP_BXBX9LegnsdgIWhO6gTtsL_WZvr736_-gFAKiG7v_C4lnYu0muTtNczWcqSTbJ9VmGp-rFlwWp_rfQ2L1JblSYlu6USniLrNn0Ntk4rE7t75Cf4ISQ-25jCldlF1OaDel7C3Zk6Z4qJuMM61aAu8GBOsjBLOjH0eQz7Y4AnjLYMVvaVwYrin-3yTZtq7HOcuTxpdtUpTH9gETCDNOjKNZAqPLK5hQwOd2peA4MkPWppZ0c81ASMDz67psCA4Qh-mXRDdoHg8Ty5Coph-0iLyGHR-jxVFuYFsYZ3yUnlyLme2Q9hbkfEOpKgGwxoiZXwQ2hfccz2uHK8Q0PWqpBeC3HyFRV1rHZRxLVp_0g_ehv6TcIW76Vlwu-4Hm_VpGoQkolAoogEF7w5latUVHlrYpoZVsN8mx5G_wMHh6p1GbTInK5C7tXrA_XIPdLTVx-qsdh6TBBg7xcquaZdYxOzT--xv1Df6My-ffcFTw8fwVPyQb4heht7-jgEbnmLZqXIGNwi6xPxlP7GCDkRD9Z2Colny7bOfwCwIZ_Xw
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELagk0AT4nWMooGMxMc5TeLUST5WVbuBtFGJFsqnyHbc0S1LojZljD_JX-KuTirYgGnforycc9Kd_Zzv7jEhb1XMPeHriKWxiVkQuJpFXCvma60jHslYBdg7fHQsDifB-2l3Wvdxr3thTk-0o85PbTsDEjTl1fpmx-cd3gFw4uC-tFOms7tkS2BWqUW2Jsej3hfLOxCxKPama5ZUv8vwcO-mYS4OO3MQvtn58yOAMjPvXwvSdcC5Te6v8lJeXsgs2yYPLgrMZy_P1uXsvy1Kw0dk3Khja1HOnFWlHP3jCtPjLfV9TB7WIJX2rFU9IXdM_pTcO6rT8M_IT5hVsJjdpBSu7LGktJjRjwYcw9ADuawWBRJRwPyBggZYVLmkn-fVVzqcA95kEAIbOpIaKcK_m2yf9uVCFSUW5uX7VOYp_YSVgQX2O1EkNagbxS4pgGzaqwsXGEDlE0MHJTaWZOBJ9MM3iP0liBhZFg06Ag9DvnGZWbFDLDQo4RU6XikDw4KcxQ6ZDAfj_iGrT4ZgOgCIyESs_EBxhbWz3RBiQi6EH6WRiIWRRrizVJhAp91AzFwlDOAAHcrUE25sRKqCmD8nrRzGfkGoJwCDpQiDPAkPAhW6vlYul26oedSVbcIb80h0TZuOp3dkSZO-f3fQT64aVZuwzVelVfiG98PG8pIa-lhIk8DKdsOXe42hJvX0s0wgTkQePcCKbfJm8xgmDswGydwUq2XicQ_CUSR8a5Nda-CbX_U5qA4DtImzsfhreoAz_eVvvD_cIrHdvP_V4OVtB9kjrWqxMq8ADVbqde39vwCmvlve
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+Incidence+of+Severe+Gastrointestinal+Events+With+First-Line+Paclitaxel%2C+Carboplatin%2C+and+Vorinostat+Chemotherapy+for+Advanced-Stage+Epithelial+Ovarian%2C+Primary+Peritoneal%2C+and+Fallopian+Tube+Cancer&rft.jtitle=International+journal+of+gynecological+cancer&rft.au=Mendivil%2C+Alberto+A.&rft.au=Micha%2C+John+P.&rft.au=Brown%2C+John+V.&rft.au=Rettenmaier%2C+Mark+A.&rft.date=2013-03-01&rft.pub=Elsevier+Inc&rft.issn=1048-891X&rft.volume=23&rft.issue=3&rft.spage=533&rft.epage=539&rft_id=info:doi/10.1097%2FIGC.0b013e31828566f1&rft.externalDocID=S1048891X24019042
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1048-891X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1048-891X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1048-891X&client=summon